Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Surgery For Long Bone Fracture

• Drug: Tranexamic Acid plus standard of care
  
  Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + Standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
• Procedure: Standard of care
  
  Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss

• Experimental: A
  
  Tranexamic Acid plus standard of care
  Intervention: Drug: Tranexamic Acid plus standard of care
• B
  
  Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss.
  Intervention: Procedure: Standard of care

Inclusion Criteria:

• Patient undergoing surgery for fracture shaft of femur

Exclusion Criteria:

• Patients with a platelet count less than 100, 000/mm3 or history of thrombocytopenia
• Patients with known coagulopathy
• Patients with anemia (hemoglobin levels less than 8 mg/dl or hematocrit <24%)
• Patients with documented DVT or PE at screening or in past three months
• Patients having known hypersensitivity to tranexamic acid or any other constituent of the product
• Patients with any associated major illness (e.g., severe cardiac or respiratory disease)
• Anticoagulants (other than LMWH or heparin in prophylactic doses to prevent deep vein thrombosis), direct thrombin inhibitors or thrombolytic therapy administered or completed within last week